Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 12:35pm CET

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUYE PHARMA GROUP LTD
03/06 LUYE PHARMA : Obtains Clinical Trials Approval for Rivastigmine Multi-day Patch ..
03/02 LUYE PHARMA : Nodded for Clinical Test of Products
03/01 LUYE PHARMA : First Step towards Integrating European TDS Business
02/28 LUYE PHARMA : 3 products added to National medical catalogue
02/25 LUYE PHARMA : Announcement - approval to develop buprenorphine transdermal patch..
01/10 LUYE PHARMA : Adoption of employees share award scheme
01/10 LUYE PHARMA : Monthly Return of Equity Issuer on Movements in Securities for the..
2016 LUYE PHARMA : China`s Luye Pharma Completes Acquistion Of Acino`s Transdermal Dr..
2016 LUYE PHARMA : Chinas Luye Pharma acquires Swiss Acino unit for $260m
2016 LUYE PHARMA : Announces the Completion of Acquisition of Acino's Transdermal Dru..
More news
Sector news : Generic Pharmaceuticals
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( CNY)
Sales 2016 2 855 M
EBIT 2016 984 M
Net income 2016 877 M
Finance 2016 1 656 M
Yield 2016 0,41%
P/E ratio 2016 16,89
P/E ratio 2017 13,49
EV / Sales 2016 4,51x
EV / Sales 2017 3,57x
Capitalization 14 542 M
More Financials
Chart LUYE PHARMA GROUP LTD
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 5,49  CNY
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director
Rong Bing Yang Vice Executive Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUYE PHARMA GROUP LTD0.00%2 111
SUN PHARMACEUTICAL IND..11.01%25 726
OTSUKA HOLDINGS CO LTD-0.61%25 372
ONO PHARMACEUTICAL CO...-7.19%12 571
SHANGHAI FOSUN PHARMAC..19.66%9 867
ASPEN PHARMACARE HOLDI..-4.50%9 853
More Results